Minor histocompatibility antigens (mHags) are thought to be targets for graft-versus-host disease (GvHD) as well as for a graftversus-leukemia (GvL) effect after allogeneic stem cell transplantation (SCT). Recently, the valine/isoleucine (V/I) polymorphism at position aa119 in proteinase 3 (PR3) was identified. PR3 is mainly localized in the primary, azurophilic granules of differentiating myeloblasts. Furthermore, a membrane expression on neutrophils and endothelial cells is known. To assess the PR3 polymorphism as a possible mHag, we first screened the distribution of the aa119 V/I polymorphism by sequence-specific primed PCR in healthy blood donors (n = 191) as well as in 54 HLA-identical SCT donor/recipient (D/R) pairs. The frequencies in blood donors for PR3-119V and PR3-119I were 0.56 and 0.44, respectively. For SCT D/R pairs, 46% of the donors were PR3-119V/I, 37% PR3-119V/V, and 17% PR3-119I/I, and 48% of the recipients were PR3-119V/I, 31% PR3-119V/V and 21% PR3-119I/I. To determine if peptides derived from the PR3-119V/I variation may act as mHags we investigated whether synthetic peptides are able to induce peptide-specific cytotoxic T lymphocytes (CTLs) in vitro. According to the peptide binding motif for the HLA-A* 0201 allele decamers were chosen. We stimulated HLA-A*0201 positive peripheral blood mononuclear cells (PBMCs) of PR3-119V/V, PR3-119I/I and PR3-119V/I positive donors with the individual peptides (spPR3-119V and spPR3-119I). Prior to stimulation we used pH 3.3 acid elution to remove naturally presented peptides from the antigen binding groove of HLA-A*0201 molecules. Intracellular detection of cytokines (icIL-2 and icIFN-g) by flow cytometry was used as an indicator of peptide-specific CTL activation. PBMCs of PR3-119I/I homozygous, HLA-A*0201 positive individuals showed a significant CTL induction, when stimulated with the discordant spPR3-119V peptide. Further, an increase of icIL2/icIFN-g expression of CTLs could be detected, when stimulating homozygous PR3-119V/V PBMCs with spPR3-119I. These findings indicate that PR3 decamers are capable of inducing peptide-specific CTLs in vitro and provide evidence that PR3 may act as mHag.
Introduction -Acute graft versus host disease (GvHD) remains the major complication of allogeneic stem cell transplantation (SCT) with an incidence of 40-60% and a mortality of up to 50%. The disease is difficult to treat and several assays have been developed to try to predict the development of GvHD including the mixed lymphocyte culture reaction, cytotoxic and helper T lymphocyte precursor frequency assays. In the Northern Region of England we have used an in vitro skin explant model for predicting GvHD in MHC compatible bone marrow transplant recipients since 1988. Methods -The assay consists of incubating patient skin explants with effector cells from mixed donor versus recipient lymphocyte cultures and the subsequent detection of graft versus host reactivity by the histopathological grading (0-IV) of the skin explants. In our experience the assay is a clear predictor of GvHD in patient cohorts treated with cyclosporine monotherapy. In 1998 a prospective study funded by the European Commission was established in two other bone marrow transplant centres in Europe with the aim to assess and evaluate the skin explant model in different cohorts of patients across Europe. Results -503 slides from 135 patients were evaluated. All were graded for negative GvHR grade 0 -I or positive grade II -IV. Results from control and test slides significantly correlated between centres to the p value of 0.0001 by Chi squared analysis. Conclusions -These results showed that the skin explant assay is reproducible between centres and supports the continued use of the assay to predict GvHD in allogeneic stem cell transplant recipients.
P480 Antithymocyte Globulin (ATG) prevents severe acute Graft Versus Host Disease (GVHD) in unrelated donor transplants: two randomized studies from the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
A. Bacigalupo, A. Bosi, P. Bruzzi, T. Lamparelli, F. Gualandi, P. Alessandrino, P. Di Bartolomeo, G. Berisso, S. Bregante, A. Raiola, C. Di Gazia, A. Dominietto, R. Oneto, B. Bruno, M. van Lint (Genoa, Firenze, Pavia, Pescara, I)
We have compared in a prospective randomized study patients receiving ATG (IMTIX-Sangstat) 3.75 mg/kg/day x2 (total 7.5mg/kg) versus control patients receiving no ATG. The primary end point was acute graft versus host disease (GvHD) grade III-IV ; secondary end points were transplant related mortality (TRM) , relapse, survival. Eligible were patients with hematologic malignancies and a 6/6 matched donor, receiving cyclophosphamide and total body irradiation (TBI) as conditioning and cyclosporin (CsA) from day -7. Conventional CsA+methotrexate (MTX) was given post-transplant. 54 patients were randomized, 25 in the no-ATG and 29 in the ATG arm: median age was 28 (13-51) and 61% were in early phase of the disease. Grade III-IV aGvHD was diagnosed in 32% receiving no ATG and 34% of patients receiving 7.5 mg/kg of ATG (p=0.7). TRM was respectively 40% vs 38% (p=0.8), relapse 12% vs 6% (p=0.5) and survival 56% vs 55% (p=0.9). Because it was unlikely to meet the primary end point this study was closed. A second trial was started comparing ATG 3.75 mg/kg/day x4 (total 15 mg/kg) vs no ATG. 55 patients were randomized in this second trial, 28 in the no-ATG and 27 in the ATG arm : median age was 31 (range 14-52), and 71% was in advanced phase of their disease. Acute GvHD grade III-IV was diagnosed in 50% of the no-ATG and 11% of the ATG patients (p=0.002). TRM was 46% vs 52% (p=0.7), relapse 11% vs 15% (p=0.6) and survival 46% vs 41% (p=0.6).Causes of TRM were different in this second trial: 30% of patients not receiving ATG died of aGvHD and 11% of infections. The opposite was true for patients receiving ATG (10% GvHD and 31% infections ). In both trials patients receiving no ATG had a higher incidence of extensive chronic GvHD (overall 62% vs 39%, p=0.07) . These two trials suggests that: (a) ATG , 15 mg/kg in the conditioning regimen, but not 7.5 mg/kg, significantly reduces the risk of grade III-IV aGvHD (b) this does not translate in a reduction of TRM because of an increased risk of infections and (c) survival is unchanged, though the incidence of cGvHD may be reduced in patients receiving ATG.
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Genital GVHD after allogeneic bone marrow transplantation S. Spinelli, S. Chiodi, A. Bacigalupo, A.M. Raiola, G. Berisso, S. Costantini (Genova, I) Some case of genital GVHD were reported by authors in the last years. In order to find out the incidence of genital GVHD in our patients we did a cross-sectional study among 217 patients who underwent allogeneic BMT from 5/82 to 11/99 at S.Martino hospital and had a regular gynaecological follow-up. The average age at BMT was 31 years and the follow-up from BMT was 7-217 months ( 31,5 median) Following symptoms and signs were collected to identify genital GVHD: Symptoms: burning with urination, burning, soreness, dysuria, dyspareunia, impossibility to have sexual intercourses. Signs: vaginal dryness, vulvar redness, pain by straining the labial, sticky leukorreha, dark red taches (vulvar denudation), leukokeratosis, introital stenosis, vaginal adhesions, vaginal obliterative stenosis. The onset of genital GVHD was 1-119 months after BMT (average 15 months); clinical remission was seen in the 84% after 2-157 months (27 average); today it persists in 16% of patients. Acute GVHD: 12/109 (11%) showed evidence of genital GVHD in the first 100 days.
Chronic GVHD: 41/197 (26%) developed genital GVHD after the first 100 days and it was minimal in 49%; moderate in 39%; severe in 12%. Among patients with chronic genital GVHD, 73% had some degree of global GVHD; in more of 70% the corticosteroid therapy was been decreased 6-1 months before the onset of genital lesions. In seven patients severe and disabling lesions were seen: 1 pt. had haematometra for obliterative stenosis of the cervix ( 75 months after BMT) 2 pt. developed vaginal obliterative stenosis ( 22 and 41 months after BMT respectively ) 1 pt. had vaginal narrowing and subsequently vaginal Ca in situ ( 40 months after BMT) 3 pt. developed soft vaginal adhesions (30, 15 and 37 months after BMT respectively). Genital GVHD can affect the sexual life seriously and for a long while, making the quality of life worse. We suggest the importance of detect precociously genital GVHD in both female and male patients, in order to avoid the more severe lesions.
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Both Fas and TNF are involved in human Gasto Intestinal (GI) GVHD G. Socié , J.Y. Mary, M. Lemann, M. Daneshpouy, E. Glukman, J.C. Ameisen, A. Janin (Paris, F) While TNF is the main mediator of apoptosis of GvHD of the GI tract in rodents, little is known about the respective role of Fas and of TNF in GvHD of the GI tract in humans. From 03/1996 to 12/1999, 258 were transplanted and 94 patients (pts) had an upper GI-biopsy. Among these 94 pts (median age 34y), 58% were male, 93% underwent transplantation for Leukemia or lymphoma (early disease; 57%), and 30% were grafted from an unrelated donor. TBI was used in 46% of the pts. Most (76%) pts received the association of CSA and MTX, and 12% had T-cell depletion for GvHD prophylaxis. Pathology examination looked for the cellular infiltrate (CI) (cell types, intensity), the intensity of edema and of inflammatory reaction, apoptosis of epithelial cells and of the CI (TUNEL), and the expression of Fas, TNF, and of the TNF receptors (p55 & p65). Pathological evidence of GvHD was found in 75.5% of the cases (pathological stage Ͼ2.in 54%). Edema and the inflammatory reaction was marked in 75% and 69%, respectively. In addition to lymphocytes, the CI infiltrates contained significant numbers of eosinophils in 40%, macrophages in 29% and PMN in 45%. The TUNEL assay disclosed significant apoptosis of epithelial cells in 75% of the cases and in 51% of the cells from the CI. FAS was expressed by 55% of the cells from the CI (and in 1% by the epithelial cells), the TNF receptors were both expressed in 60% of the cases and TNF in 87.5%. If patients had nausea or vomiting only; in 12%, pathological evidence of GvHD was found; on the contrary, in another 12% of the patients, no pathological signs of GvHD were found. The predictive and prognosis value of the TUNEL assay, FAS, TNF and TNF receptors expression, and of the CI characteristics are under study. However, from these preliminary results it is already clear that both the TNF and the FAS pathways are implicated in the development of GvHD of the GI tract, in humans. Finally, preliminary analysis of the whole cohort of 258 pts did not found evidence of any bias of selection of the 94 pts; in particular in the incidence of grade Ͼ II acute GvHD.
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The significance of IL-10 and TNF gene polymorhisms to acute GVHD and cytokine serum levels A. Nordlander, M. Uzunel, J. Mattsson, O. Ringden, M. Remberger (Huddinge, S) Aim: We analyzed cytokine gene polymorphism to determine whether specific alleles were correlated to severe acute GVHD. Introduction: Gene polymorphism is common in the transcription control regions of some cytokines. Whether this polymorphism is associated with different expression efficiency is not completely clear. In previous studies it has been shown that the genotype d3/d3 of TNFd and higher allele numbers of IL-10(-1064) were correlated to more severe GVHD. It is well known that TNF-alpha is associated with acute GVHD. Materials and Methods: 246 patients were included in the study. 103 patients received stem cells from HLA identical siblings and 143 from MUD. Underlying diseases were leukemia (n= 208), solid tumors (n=13), metabolic disorders (n=13) and others (n=13). Conditioning regimen consisted mainly of Cyclophosphamide (Cy) + TBI (n=176) and Cy + Busulphan (n=62). GVHD prophylaxis was mainly a combination of CyA and methotrexate (n=199). PCR products of TNFd and IL-10(-1064) were run on 10% polyacrylamide gels and visualized with silver staining. Allele frequencies were similar as reported by others. Serum levels of TNF-alpha were quantified with ELISA in 200 patients. Results: Risk factors for developing aGVHD in this study were treatment with OKT-3, high serum levels of TNF-alpha during conditioning and CMV seropositive patient. Neither the genotype d3/d3 of TNFd nor higher allele numbers of IL-10 were associated with more severe aGVHD. However, patients possessing allele number 13 of the IL-10 gene had significantly more aGVHD II-IV (p=0.03). There were no correlation between TNFd gene polymorphism and TNF-alpha serum levels. Conclusion: Our results do not accord to previous studies. In our study allele number 13 of IL-10 gene was associated with severe aGVHD. Further studies are needed to evaluate the correlation between cytokine polymorphism and aGVHD.
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Late relapse in patients with Graft-Versus-Host Disease (GVHD) A. Ferrant, N. Straetmans, D. Latinne, E. Van Den Neste, L. Michaux (Brussels, B) A decreased relapse incidence (RI) might be caused by the graft-versus-malignancy effect of GVHD. This effect has been reported to be sustained. Late relapses (Ͼ4 y) occurring in patients who had GVHD prompted us to analyse our data. The RI of 226 consecutive patients who had an allogeneic hematopoietic stem cell transplantation was analysed. The diseases included AML (n=84), ALL (n=33), CML (n=47), lymphoma (n=29), MM (n=16), MDS/MP (n=15), CLL (n=2). Conditioning was with single dose TBI (n=181), Bu (n=40), other (n=5). GVHD prevention included CsA + MTX (n=136), CsA (n=51), CsA + MoAb (n=13),
S172
CsA + MTX + MoAB (n=13). Five patients received a graft from an identical twin. At the time of transplant, disease stage was split in 3 categories for each disease, i.e. good (n=109), intermediate (n=77), and high risk (n=40). GVHD occurred in 130 patients (acute: 89, chronic: 4, acute and chronic: 37). Age, stage at transplant, disease, conditioning, and GVHD prevention were not statistically different between patients without and with GVHD. The 4-y RI in patients without GVHD was 49 +/-5%, vs 34 +/-4% with GVHD (p=0.05). In multivariate analysis also, GVHD was a significant factor for RI at 4 y (RR: 0.8, CI:0.72-0.89, p=0.03). At 10 y however, the RI was 49 +/-6% and 49 +/-5% in patients without and with GVHD, respectively. The 10-y survival was 38 +/-6% in patients without GVHD and 47 +/-4% in patients without GVHD (NS). No patient without GVHD relapsed beyond 4 y (0/26 vs 9/42, log rank p=0.02). 5/9 late relapses in patients with GVHD occurred in CML. The remaining patients with late relapse had AML (n=2) and ALL (n=2). 2/9 were at high risk for relapse at transplant. GVHD was acute in 5, chronic in 2 and both acute and chronic In 2 patients. Additional immunosuppressive therapy was needed in 3/9. The data suggest that late relapses might occur more often in patients with GVHD, and that GVHD might only delay relapse.
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Feasibility of delayed donor lymphocyte infusions, collected under GCSF, in adult haplo-identical transplants.
C. Jacquy, P. Lewalle, A. Delforge, P. Crombez, D. Bron, P. Martiat (Brussels, B)
Haplo-identical stem cell transplantation is becoming mastered as far as conditioning regimen, GVHD and graft take are concerned, but the results are still hampered by post-transplant infections and a high relapse rate. Donor lymphocyte infusions, even at low doses, have been reported exceedingly toxic. We thought of taking advantage of the diminished alloreactivity of Tcells harvested under G-CSF and used these lymphocytes for DLI. Six consecutive patients received 1 x 104 CD3 per kg at day 28 post-transplant. Patients: 2nd refractory relapse of AML (30), 3rd refractory relapse of NHL (47), refractory secondary RAEBT (29), primary refractory B-cell ALL (19), refractory relapse of Ph+ ALL (18) and primary refractory T-cell ALL (40). Conditioning regimen: Melphalan, 60 mg/m2 at days -9, -8 , Fludarabine 40 mg/m2 on days -7 to -3 , TBI (10 Gy in 5 fractions), ATG, 5 mg/kg from day -6 to day -2 and cyclosporin from day -7 to day -2. Ara-C 1g/m2 BID was added at days -18 and -17 in case of progressive disease. No post-transplant GVHD prophylaxis was given. PBSC were T-cell depleted using an Isolex 300i (CD34 positive selection, T and B negative selection) and the CD3 dose in the graft adjusted to 5x104 CD3/kg. The CD34 cell dose ranged from 2 to 6 x 106/kg. No G-CSF was given the first days post-transplant, when presentation of host antigens is likely to occur. All patients engrafted, with ANC Ͼ 1x109/l between day 10 and 14. No GVHD was observed, except a transient grade I reaction in patient 2. At day 28, DLI were performed. Results: GVHD occurred 2 weeks after DLI in 4/6 patients. In three, prednisone, 1 mg/kg, easily controlled GVHD and could rapidly be tapered to minimal doses (4 mg every other day in one patient, still in the decreasing phase in 2 others: 8 mg/day in one and 16 mg/day in the second). In the fourth patient, a combination of cyclosporin and prednisone had to be used before tapering prednisone. Five patients are in CR (2 to 14 months), with minimal doses of prednisone, and with 3 months CD4 counts above 200/ml in the four patients currently beyond this point. There was no TRM. One patient died at 3 months from CNS relapse. We conclude that DLI (104 CD3/kg collected under G-CSF/) are feasible in adult haplo-identical transplant. They result in moderate GVHD easy to control with minimal long-term immune suppression. They increase the CD4 counts early post-transplant and could reinforce anti-infectious immunity and GVL reactions.
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Chronic graft versus host disease after allogeneic peripheral stem cell transplants: incidence, duration, response to therapy and risk factors
Since 1995 we have performed 100 allogeneic PBSCT. In order to examine cGVHD we analyzed pts with AL, CML and MM, transplanted before Dec 1998 and who survived at least 90 days after transplant (N=55). Median age was 41(range 19-57). Conditioning treatment consisted mainly of BU-CY except for the 15 MM who received TBI+Melph+EDX. The GVHD prophylaxis was short term MTX+CsA, except for 2 pts. Pts were grouped in early (39) or advanced phases (19). Cumulative rate of cGVHD was 56% (31/55) (95%CI:49-63); moderate and severe was 14/55 (25%); limited (mild) cGVHD was 31%. Pts were subgrouped in 2 categories: no or mild cGVHD and moderate and severe.The actuarial median time to cGVHD was 310 days (95%CI:77-543), while the median projected actuarial time to cGVHD resolution was 1109 days. 7/31 patients who developed cGVHD died: 3 because of cGVHD and 3 pts with cGVHD. Additional immunosoppressive drugs (beyond Csa) were necessary in 14/31 pts (1 drug), 10(2), 2 (3) and 1(4).Of the 23/31 pts surviving more than1 yr, cGVHD disappeared in 10 pts who had all immunosoppressive therapy discontinued, substantially decreased in 6 patients, of whom 4 had therapy stopped, and was still present for 7 pts, 4 of whom requiring therapy. Univariately, no association between cGVHD and recipient' and donor's age, number of total cells and the T-lymphocyte infused, interval between diagnosis and BMT, sex mismatch was present. However, a significant association was found between cGVHD and recipient's sex (males more than females, p=0.047), diagnosis (p=0.011; CML pts were more prone to cGVHD than MM and AL), previous aGVHD (p=0.007), and disease phase at BMT (p=0.05, only for AL pts). Subsequently, a multivariate analysis by logistic regression has been performed, including in the model all the interaction terms suggested by the preliminary analysis. We found that previous grade 2-4 aGVHD resulted in a significant higher risk of cGVHD (RR=5.12 95%) in comparison with no or grade1. In addition we also found a statistically significant interaction between sex (Male) and diagnosis (CML), owing to a relative risk of cGVHD of 7 folds for a CML male pt as compared to a MM male pt. In conclusion, the association between sex and cGVHD we observed in the preliminary univariate analysis should be attributed to the increased risk of cGVHD for CML male pts. Finally, maybe because of lack of power, the abovementioned link between cGVHD and disease phase in AL resulted just below statistical significance.
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Th1/Th2 cytokines and soluble adhesion molecules after allogeneic hematopoietic stem cell transplantation: influence of stem cell source and use of Dalteparin H. Ç elebi, M. Ö zcan, M. Arat, K. Dalva (Ankara, TR)
As initial concerns over the high risk of GVHD which may result from the imbalance between Th1 and Th2 cells after allogeneic PBSCT compared to BMT have not been confirmed, debate is still ongoing. Heparin has been demonstrated to prevent GVH reaction in animal models by an unclear mechanism. In this study we intended 1) to evaluate the balance between the levels of Th1 (TNF-a and IFN-g) and Th2 (IL10) type cytokines and 2) to persue the levels of soluble adhesion molecules (SAM) (sICAM, sVCAM, sL-Selectin) according to the stem cell source or the use of low molecular weight heparin for prophylaxis. Thirty patients with various hematologic malignancies (CML:18, AML:9, ALL:2, MM:1) who underwent allogeneic stem cell transplantation from their HLA identical siblings (PBSCT:14 and BMT:16) were randomized to use dalteparine (Fragmin 2500U/day sc from day -9 to +100 ) (n=16) or not (n=14). Blood samples were obtained on days -9, infusion day, aplasia and on engraftment day. Cytokines and SAM levels were measured by ELISA method. In the group as a whole (n=30), weekly levels of TNF-a, IFN-g and sVCAM remained unchanged while IL10, sICAM and sL-Selectin levels decreased by conditioning regimen and increased by engraftment. The serial measurements of cytokines and SAM levels were similar in patients who underwent AlloBMT or AlloPBSCT. But while serial measurements of Th1/Th2 cytokines were stable in the BMT group, IL10 levels decreased after conditioning regimen and increased during engraftment in the APBSCT group (p=0.005). There were no significant differences in the levels IFN-g, IL-10 and SAM between the patients who received dalteparin and who did not receive. But TNF-a levels were higher on infusion and engraftment days to in dalteparin receiving patients in comparision to patients with no dalteparin (p=0.047 and 0.025 respectively). In patients who had aGVHD, while Th1 type cytokines were stable , IL10 levels, which remained unchanged in patients without aGVHD, were higher on aplasia and engraftment days compared to the infusion day. Moreover on day +100, IL10 levels showed positive correlation with the severity of aGVHD (r=0.517, p=0.049). IL10 and sICAM levels increased in patients with chronic GVHD. In conclusion, neither the stem cell source nor the dalteparin prophylaxis had any effect on Th1/Th2 types cytokines and SAM. Although baseline cytokine or SAM levels could not predict complications seen after allogeneic transplantation such as aGVHD, IL10 levels were correlated with the severity of aGVHD.
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In vitro assessment of calcineurin activity as a therapeutic index of immunosuppression induced by ciclosporine or tacrolimus in chronic GvH disease S. Sanquer, H. Rafi, P. Beaune, C. Pautas, K. Yacouben, M. Kuentz, C. Cordonnier (Paris, Cré teil, F) Both ciclosporine and tacrolimus act by inhibiting the phosphatase activity of calcineurin. It has been previously shown that a decrease in calcineurin activity correlates with a decreased IL2 and interferon-gamma production and an impaired T cell proliferation. Because of inter-individual variations in the kinetic of the drugs, the assessment of calcineurin activity on T lymphocytes could be a more accurate technic than blood levels to monitor the optimal therapeutic regimen with these drugs. The goal of this pilot study was to assess the calcineurin activity under ciclosporine, then under tacrolimus, in patients treated for chronic GvHD. Patients were enrolled in case of chronic GvHD resistant after 2 months of a first line regimen of steroids and ciclosporine. After informed consent, patients were switched from ciclosporine to tacrolimus, and studied for calcineurin activity on the last day of ciclosporine treatment, then on days 15 and 60 of tacrolimus treatment at a dose of .06 mg/kg bd orally. Methods: Blood samples were collected before, and 1, 2, 4, 6 and 10 hours after dosing. CsA and tacrolimus were measured in whole blood by immunoenzymatic assays and the activity of calcineurin was determined in mononuclear cells isolated from whole blood by quantifying by HPLC the dephosphorylation of phospho-RII peptide, a peptide whose sequence represents the phosphoryation site of the regulatory subunit of cAMP-dependent protein kinase. Results: The data for the first three patients are summarized in the table
CsA
Tacrolimus day Tacrolimus day 15 60 Trough calcineurin activity* 3.3 (2.1-4.5) 4.1 (2.4-5.5) 4.1 (2.9-4.6) Inhibition ratio 27% (6-48%) 7% (0-21%) 12% (0-21%) Stimulation ratio 3% (1-5%) 63% (0-112%) 41% (0-113%) * expressed in mg RII/min/mg proteins as mean (range) Mononuclear cells derived from patients with resistant GvHD express very high calcineurin activity compared to what is usually observed in healthy volunteers or stable renal transplant patients, who are usually below 1mg RII/min/mg proteins. These high levels of calcineurin activity were maintained troughout the 12 h dosing interval whatever the drug administred. This reflects a poor biological activity of both drugs in these 3 patients, which was consistent with the poor clinical efficacy observed. In vitro assessment of calcineurin activity appears as a promising index to estimate the degree of immunosuppression afforded by ciclosporine or tacrolimus. Acute graft versus host disease (aGvHD) of the gastrointestinal tract is a severe complication after allogeneic bone marrow transplantation. In addition to the clinical grading an objective and reliable noninvasive method to assess extend, severity, course and prognosis of aGvHD of the bowel is needed. Recently, high resolution ultrasonography (HRU) and color Doppler imaging (CDI) have been introduced to evaluate inflammatory and ischemic bowel diseases. Thus, these techniques were utilized in this study to describe the sonographic findings in aGvHD of the bowel. Twelve patients with suspected acute intestinal GvHD and/or severe cutaneous aGvHD were investigated by HRU and CDI. Structure and thickness of the bowel wall and the blood flow pattern in the superior mesenteric artery (SMA) as well as in the bowel wall were evaluated. All twelve patients showed thickened bowel wall segments, particularly in the ileocecal region. Even in patients without any clinical signs of bowel involvement (3/12) sonographic changes were observed. In all patients, in those with as well as in those without intestinal symptoms an aGvHD was confirmed histologically. In 6 patients with severe diarrhea sonographic signs of secretoric diarrhea (changes of motility and reduction of Kerckring's plicae circulares) were detected. Patients without clinical symptoms and those with a low grade (I°and II°) intestinal aGvHD had no sonographic signs of secretoric diarrhea. In 8 patients an increased arterial blood flow was demonstrated as a typical sign of an inflammatory bowel process. In contrast, 4 patients showed the unique pattern of ischemic bowel wall lesions and high resistance flow pattern in the SMA in conjunction with a thickened bowel wall. These patients did not respond to immunosuppressive therapy and died. However, all patients with a normal or increased arterial blood flow responded at least to the second or third line immunosuppressive treatment. To conclude, HRU is a useful tool to detect acute bowel GvHD even prior to clinical symptoms. Furthermore, the pattern with a main manifestation in the ileocecal region might help to differentiate between an infection (e.g. pseudomembranous colitis or CMV colitis) and aGvHD of the bowel. Taken together, HRU and CDI can be applied to define the severity of aGvHD and to identify patients with a poor prognosis. In acute leukaemia most relapses occur in the first six months post transplant. Therefore reduced immunosuppression in the early posttransplant phase is desirable in these patients (pts). In comparison to adults, children undergoing BMT generally require less intensive GvHD prophylaxis. Yet, there is a dearth of information on children transplanted with peripheral blood from matched sibling donors (MSD). We assessed the feasibility of single drug GvHD prophylaxis with CSA 1(2) mg/kg/d i.v. (p.o.) until day 80 with subsequent tapering of CSA by 20%/week in 7 children (age 6-14 yrs, median 13 yrs) undergoing MSD-PBSCT for malignant disease (ALL=4, AML/MDS=3). PBSCs contained 5,1x10e6 CD34+ cells/kg (median; 4,3-10,0x10e6) and 4,3x10e8 CD3+ cells/kg (3,3-5,3x10e8). Engraftment was achieved in all pts. after 10-14 days. All pts developed acute GvHD with 5/7 pts experiencing Ͼ= Grade II disease. As a consequence, these pts required intensification of GvHD-therapy with increased CSA-therapy as early as d 10-20 with additional cortison in 4/5 pts and mycophenolatmofetil as a third component in 3/5 pts.
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Two of these pts died of infectious complications (fungal and protozoal) d 63 and 127. One pt relapsed early (d 101).
In 2/4 remaining pts, CSA was tapered as intended without any signs of cGvHD. Early tapering of CSA lead to development of hepatic cGvHD in 2 pts (d +105 and +152) requiring continuation of CSA or FK506 beyond day +235. Thus, our data suggest that low dose single agent CSA in children undergoing MSD-PBSCT is associated with an increased risk of severe acute GvHD. The high incidence of early onset acute GvHD required salvage treatment for GvHD in the majority of patients counteracting our initial treatment intention and carrying the risk of life-threatening infections. While reduced immunosuppression may be benefitial in children receiving bone marrow from MSD, this strategy seems problematic in children transplanted with PBSC. Further studies defining the optimal GvHD-prophylaxis for children receiving matched-related PBSCT are urgently warranted. Supported by the Elterninitiative Kinderkrebsklinik Dü sseldorf e.V. The aim of this study was to clarify the optimum number of CD34+ and CD3+ cells that must be left in the graft to allow reliable engraftment, prevent severe acute GVHD, and decrease transplant related mortality (TRM) in allotransplants with TCD. Patients (n=101), 42y (16-55), with haematological malignancies in early (55%) or advanced (45%) stage received either bone marrow or G-CSF mobilised PBPC, T-cell depleted by means of elutriation (allo-BMT/Elu) or CD34+ selection (allo-PBT/CD34+), respectively, from HLA identical sibling donors. Conditioning regimen consisted on Cy 120 mg/kg plus TBI (13 Gy in 4 fractions), and GVHD postransplant prophylaxis on CsA+PDN or CsA. The specific protocol, CD34+ and CD3+ cell content in the graft, and the actuarial probability of graft failure, acute GVHD II-IV, and TRM, are shown in the table. Age of the patients, diagnosis, and disease stage were well matched between the three groups. [Insert table here] In conclusion, infusion of a graft containing a median of CD34+ cells 4x106/kg and CD3+ cells 0.3x106/kg resulted in sustained engraftment without significant GVHD and with the lowest TRM. In adults, allogeneic peripheral blood stem cell transplantation (PBSCT) has been shown to be advantageous with regard to rapid engraftment and reduced treatment-related toxicity. While the incidence of aGvHD following PBSCT is largely comparable to bone marrow transplantation (bmt), the issue of a potential increase in cGvHD post PBSCT remains controversial. Currently, information on the outcome of PBSCT in children is sparse. In our center, 42 children aged 0,5 to 17,4 years received G-CSF mobilized PBSC after myeloablative therapy from a related (rel) (n=28) or an unrelated (unrel) donor (n=14) (1995) (1996) (1997) (1998) (1999) (2000) . 5 additional pts transplanted without stable remission during that time were excluded from the study. Pts received 7±3 E6 vs 12±5 E6 CD34+cells/kg bw (mean±SE) for rel vs. unrel PBSCT. GvHD prophylaxis in the rel tx group consisted of CSA alone (13/26 pts) or a combination with MTX (10mg/m2ds 1,3,6). All pts transplanted with unrel. PBSC received MTX plus CSA with CSA levels averaging 110-230 mg/dl and anti-IL-2R Ab (BT563) as a third component in 7/14pts. Engraftment was comparable in rel. and unrel. tx pts with neutrophilsϾ500/µl on ds 13 and 15 post tx and last platelet or packed red cell transfusion on ds 32 vs 37 respectively. Of note, there was no difference in survival with 0,68±0,1 vs 0,71±0,12 EFS (mean obs. period 27± 4 vs 14,5 ± 3 months) in rel. and unrel. PBSC recipients.7/26 pts died (5 DOC, 2 DOD) post rel and 4/14 pts post unrel PBSCT (4 DOC).Acute GVHD *III was observed in 6/28 rel and in 5/14 unrel tx pts. 22 pts in the rel and 10 pts in the unrel tx group were available for cGvHD analysis with the incidence as high as 60% and 90% respectively. Thus, in children, PBSCT from a rel. or unrel. donor results in rapid myeloid engraftment. EFS post tx with PBSC from a sib donor is comperable to bmt. EFS in the small group of unrel. tx pts is high considering that 11/14 suffered from acute leukemia or MDS. Yet, all but one survivor of the unrel tx group were afflicted by cGvHD indicating that children transplanted with PBSCT may require intensified Matched unrelated donor transplant has an increased risk of severe graft versus host disease and transplant related mortality. ATG has been used to decrease GvHD at the cost of serious side effects like graft rejection, secondary lymphoma and an increased relapse rate have been reported. We conducted a retrospective analysis of 2 ATG preparations Fresenius (n = 80, average 90 mg/kg bw) (range 20 -90 mg/kg) and Merieux (n = 66, average 10 mg/kg bw) (range 5 -20 mg/kg) and compared with a no-ATG group (n = 188). Age, sex, use of bone marrow versus blood stem cells, HLA match versus mismatch were comparable in the 3 groups.
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Results: Table 1 Conclusion: Our results have shown that ATG Fresenius decreases the incidence of acute GvHD and TRM. However a trend to increase relapse rate in patients receiving Fresenius ATG was observed thus indicating that a prospective randomized study is needed in order to evaluate the role of ATG in HSCT.
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Antithymocyte globulin in the conditioning for unrelated donor transplantation: comparison of two regimens L. Volin, E. Juvonen, T. Parkkali, E. Elonen, T. Ruutu (Helsinki, FIN) Antithymocyte globulin (ATG) is commonly included in the conditioning regimen for unrelated donor transplantation to reduce the risk of rejection and GVHD, but the optimal mode of administration is not known. We present a retrospective comparison of two ATG regimens. During the period from 1993 to August 2000 94 patients with a malignant haematological disorder underwent an allogeneic transplantation from an unrelated donor. 38 patients had CML, 24 AML, 16 MDS, 14 ALL, and 2 NHL. 42 patients were in CR I of acute leukaemia or CP I of CML. All donors were at least 6 antigen matched, and the grafts were unmanipulated. All patients received GVHD prophylaxis with cyclosporine and a short course of methotrexate, and 73 patients were also given low-dose methylprednisolone. The first 55 patients received Atgam (R) 20 mg/kg/day on days -5 --3, the last 39 patients Thymoglobulin (R) 4 mg/kg/day (5 patients 10 mg/kg/day) on days -3 --1. One patient in each group received a second transplantation because of no graft take. In the group given Atgam the incidence of acute GVHD was 62%, that of grade II -IV 49% and grade III -IV 20%, whereas in the group given Thymoglobulin the incidence was 18%, that of grade II -IV 13% and grade III -IV 8%. The day 100 survival was 82% in the group given Atgam and 85 % among patients given Thymoglobulin. The follow-up of the latter group is too short for the evaluation of the risk of relapse. CMV viremia (CMV ea-positive) developed in 58% of the patients given Atgam and in 69% of those given Thymoglobulin; the median time of onset (range) was day 48 (14-130) and day 33 (18-81), respectively. Although minor changes were made during the study period to the mode of administration of the other components of the GVHD prophylactic regimen, and the development of tissue typing probably contributed to the improved results, it is obvious that the change in ATG administration was the main reason for the reduction of acute GVHD; the fall in the incidence of acute GVHD coincided with the change in the ATG protocol. The omission of corticosteroid from the prophylactic regimen did not affect the results. The present findings suggest that, in the doses used, Thymoglobulin given on days -3 --1 causes heavier immunosuppression and is more effective in the prevention of acute GVHD than Atgam given on days -5 --3. Steroid resistant GVHD remains a major cause of treatment related mortality following allogeneic stem cell transplant. ABX-CBL is a murine IgM monoclonal antibody that recognizes CD147, an antigen highly expressed on activated T, B and NK cells, monocytes, and dendritic cells. In a recent multicenter, phase II study, 59 patients with steroid resistant acute GVHD were treated with ABX-CBL. Overall, 26 of the 51 evaluable (received at least 4 infusions of ABX-CBL) patients (23 of 43 treated at doses Ͼ 0.1 mg/kg) demonstrated an improvement of their acute GVHD. 13 patients achieved a complete response (an IBMTR Index of 0) and 13 a partial response (an overall improvement of at least two indices on the IBMTR Index). 26 of 50 patients (52%) treated at doses Ͼ 0.1 mg/kg survived at least 100 days after the first dose of ABX-CBL. The dose limiting toxicity (DLT) was severe myalgia, which generally responded to treatment with IV narcotics and resolved without sequelae. Data are available for 13 patients who were enrolled into an extension study for additional treatment with ABX-CBL. 5 of these patients were treated at the 0.3 mg/kg dose (prior to dose reduction due to the DLT) and 8 at 0.2 mg/kg. ABX-CBL was administered daily for 7 days and additional courses were permitted on a case by case basis. 10 of these 13 patients received at least 4 infusions of ABX-CBL and were evaluated for response. 5 of 10 (50%) evaluable patients (all in the 0.2 mg group) had a complete (n=1) or partial (n=4) response. All patients were evaluated for survival and safety. 6 of 13 patients (46%) were alive 180 days after the initiation of treatment with ABX-CBL. No new dose limiting toxicities were observed. Patients who were not eligible for the Phase II study were enrolled into a compassionate study and the data are now being reported. 20 patients were treated with 0.2 mg/kg/day of ABX-CBL for 7 days (additional courses of ABX-CBL were permitted on a case by case basis) and response data are available for 19 of these patients. 15 patients with acute steroid resistant GVHD were enrolled and 6 (40%) responded. 4 patients with chronic GVHD were enrolled and 1 patient (25%) responded. The GVHD response rates to ABX-CBL observed in these 2 new studies are similar to the response rates observed in the phase II study. ABX-CBL therefore shows promise in the therapy of steroid resistant acute GVHD. A multicenter randomized study comparing ABX-CBL with ATG is currently underway.
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Influence of graft source on graft versus host disease, relapse and survival following T-cell depleted allogeneic stem cell transplantation We report the results of a retrospective single-center study comparing engraftment, acute and chronic GVHD, relapse and survival in patients with malignant hematological disorders transplanted with allogeneic peripheral blood stem cells (alloPBSCT, n=40) or bone marrow cells (alloBMT, n=42). All transplants were T-cell depleted by in-vitro incubation with the Campath-1 monoclonal antibody. Primary graft failure occurred in none of the patients receiving an alloPBSCT compared with 3/42 of the recipients of an alloBMT. In addition, two patients in the alloBMT group showed no platelet engraftment. Recipients of PBSC had a more rapid recovery of neutrophils (median 14 days) compared to BM transplant recipients (median 32 days). Platelet recovery was also accelerated in PBSC recipients compared to BM recipients (11 versus 38 days). There was a marked increase in the incidence of acute GVHD Ͼ grade 2 and chronic GVHD in patients after alloPBSCT (18% and 23%, respectively) compared to patients receiving alloBMT (5% and 8%, respectively). This increase in GVHD was mainly confined to GVHD of the skin, since only one patient in the PBSC group suffered from GVHD of the liver. Grade III-IV acute GVHD was only observed in one BM graft recipient and in none of the patients receiving PBSC. The two-year cumulative incidence of relapse was similar in both groups (47%). At six months after transplantation, transplant related mortality (TRM) was lower in PBSCT recipients than in BMT recipients. However, at a follow-up of three years TRM was similar in both groups. The disease-free survival rate at three years after transplantation did not differ between the groups (42% for PBSCT and 41% for BMT recipients). Our results indicate that Tcell depleted alloPBSCT compared to alloBMT is associated with a more rapid hematopoietic reconstitution and a decreased TRM at 6 months follow-up after transplantation. However at a follow-up of three years, no sustained survival benefits were observed.
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A predictive score for transplant related mortality (TRM) following allogeneic stem cell transplantation: day +7 serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cells dose A. Bacigalupo, M. Sormani, R. Oneto, T. Lamparelli, F. Gualandi, G. Berisso, S. Bregante, A.M. Raiola, C. Di Grazia, A. Dominietto, B. Bruno, M.T. van Lint, P. Bruzzi (Genova, I)
We have previously described a scoring system for patients undergoing hemopoietic stem cell transplantation (HSCT) based on day +7 blood urea nitrogen (BUN) and serum bilirubin levels. We have revised that scoring system on 618 allogeneic HSCT recipients using a formal multivariate approach based on two separate phases: a training and a validation phase. Day+7 blood urea nitrogen (BUN), serum cholinesterase (CHE), total proteins (TP), gamma glutamyl transferase (&#61543;GT), donor type and cell dose at transplant were the variables included in the new scoring system that was based on 522 patients with valid data (305 in the training and 217 in the validation set). All the 6 variables were strong predictors of TRM. According to the score distribution from the COX analysis we identified three groups of patients (below 25, 25-75 and above 75 percentile) classified as LOW, INTERMEDIATE and HIGH RISK. The predictive score was then tested on the validation group of patients and was proven to be highly predictive of TRM: TRM of LOW, INTERMEDIATE, HIGH RISK patients in the validation group was 15%, 40%, 69%. Patients in the high risk group had significantly more grade III-IV GvHD (p=0.0000) and significantly lower platelet counts on days +21/+200 (pϽ0.0001) as compared to intermediate and low risk patients This study confirms that patients can be classified as having different risk of TRM on day +7 after HSCT: this may allow for tailored treatment of patients post-transplant.
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Does minimal chronic GVHD exist?
C Di Grazia, F Gualandi, A Dominietto, T Lamparelli, Am Raiola, G Berisso, S Bregante, F Frassoni, A Bacigalupo (Genoa, I)
Over the past 20 years we have been scoring patients with chronic GvHD as follows: absent (0), minimal (1), if any minimal sign of cGvHD was present, also if only limited to the tongue, limited (2) and extensive (3). There is thus a discrepancy with the internationally used classification in absent, limited, extensive. In the present study we wanted to ask whether classification in 4 categories rather than 3 is justified by the outcome of 644 patients with hematologic malignancies, alive on day +100 and eligible to develop cGvHD. 99 patients were classified as absent, 309 as minimal, 192 as limited and 44 as extensive cGvHD. The actuarial 5 year transplant related mortality (TRM) was respectively 28%, 12%, 28% and 65%: TRM of patients with minimal cGvHD was significantly different from all other groups. The actuarial 5 year risk of relapse was respectively 61%, 36%, 22%, 19%: again patients with minimal cGvHD had significantly different relapse rate as compared to no GvHD and limited GvHD. Finally 5 year survival was 32%, 67%, 66%, 44%, with significant differences between absent and minimal cGvHD patients. Main causes for transplantation related mortality (TRM) are infection and graft versus host disease (GVHD). The type of conditioning regimen strongly influences the risk of GVHD and TRM. Especially for GVHD a cytokine storm beginning during conditioning has been shown. Less intense conditioning regimens with reduced toxicity have been strongly advocated for use in allogenic transplantation. The STAT protein family is known to be an important signal transducer and activator of transcription. The JAK/STAT pathway is widely used by members of cytokine receptor superfamily. We investigated the activation of STAT proteins 1, 3 and 5 at different time points in 10 pts before and after allogenic stem cell transplantation. An EMSA assay was used for determination of STAT protein activation in peripheral blood. Diseases were AML (5), MDS (2), CML (2) and NHL (1). 3 pts received non myeloablative regimes, 7 pts had conventional conditioning regimes. All pts with conventional therapy had activation of STAT proteins 1, 3 or both. In the other group 2 pt showed no activation. One pt had a activation of STAT 1 and 3 wich correlated with a severe reaction to ATG. All pt with a activation of STAT 1 and 3 died subsequently. During the post transplant period STAT protein activation was found at engraftment, during CMV infection and GVHD. These preliminary results show a reduced STAT activation during less toxic conditioning regimens. This might correlate with less intense activation of cytokine network leading to the clinically seen reduced toxicity of the non myeloablative regimens. The missing activation of STAT 5 is intriguing and should be further investigated on the cytokine level. AvWS has been mainly associated with immunoproliferative and auto-immune diseases. Only one case has been reported occurring after allogeneic SCT. We report here the course and therapeutic interventions of a patient who developed AvWS in the setting of chronic GVHD. A 43 y man received an allogeneic SCT from his HLA-id sister in 03/98 for AML in 4th CR. The patient and donor had no prior history of bleeding. The coagulation parameters were normal before transplant. Acute, then moderate chronic GVHD were treated with steroids and ciclosporine. In 11/99, a thoracotomy was planned for unexplained pneumonia. The preoperative check-up showed a prolonged activated partial thromboplastin time (APTT). Primary haemostasis, assessed in vitro with the PFA-100 instrument, was abnormal, with closure times markedly prolonged with collagen-Epinephrine and collagen-ADP cartridges. APTT was prolonged as a function of decreased factor VIII activity; vWf ristocetin cofactor activity (vWf RCo) and antigen (vWf Ag) in plasma were very low whereas platelet vWf antigen was normal (see Table) . No inhibitory activity against vWf RCo was found in vitro. Despite a poor and transient response to DDAVP, this therapeutic option allowed an uncomplicated thoracotomy. Bronchiolitis obliterans with organizing pneumonia was diagnosed. Antinuclear Ab were found in the serum. The patient refused steroids. He came 1 month later with severe epistaxis and oral lichen. Two successive therapeutic interventions were assessed:1) DDAVP. 2) IVIG (1g/kg/w for 3 w). Both improved laboratory abnormalities, however, the effects were poor and transient. Nevertheless, these, with an increase of steroids for GVHD, led to cessation of bleeding.
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